Inhibiting "anchor" molecule in stem cells may improve marrow transplant process

Share this article:

The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.

The molecule—Robo4—is found only in the hematopoietic stem cells and in the endothelial cells of blood vessels. According to the new study findings, published in Cell Stem Cell (2011;8:72-83), hematopoietic stem cells—the key components in bone marrow transplants—use Robo4 to anchor themselves in the bone marrow where they reside.

In an increasingly common alternative to traditional bone marrow transplants, repeated drug injections are administered to usher stem cells away from bone marrow and into the bloodstream, from which they can be harvested and eventually groomed into different types of cells. The Robo4 discovery, however, creates an opportunity to find agents that can block the molecule in a safer and more effective fashion.

“If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently,” explained E. Camilla Forsberg, an assistant professor of biomolecular engineering at University of California–Santa Cruz, in a statement describing her team's work.

 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Early promise against melanoma from new antibody-drug conjugate

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Aging is sped up in breast cancer survivors who underwent adjuvant chemotherapy

Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.

Subset of patients with breast cancer patients will most likely benefit from ...

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.